News | Stents Bioresorbable | October 15, 2015

SCAI: Bioabsorbable Stent Technologies Will Expand Options for Cardiovascular Disease Patients

Synergy and Absorb stents offer treatment for heart blockages without long-term complications of permanent stent components

SCAI, new bioabsorbable stent technologies, TCT 2015, Absorb, Synergy

Synergy stent image courtesy of Boston Scientific

October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients. 

One-year results from the ABSORB III trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2015 in San Francisco. The study met its primary endpoint, demonstrating the Absorb stent — which is fully absorbed by the body — performed as well as conventional stents at one year. Conducted at 193 sites, primarily in the United States, the ABSORB trial enrolled about 2,000 people with coronary artery disease.

The Society of Angiography and Cardiac Interventions (SCAI) issued a statement finding these initial data encouraging and that it looks forward to more long-term data over the next three to four years that will detail the benefits of this technology in participating patients. Although not yet commercially available in the United States, currently Absorb is available in more than 100 countries worldwide.

Last week, the U.S. Food and Drug Administration (FDA) approved Synergy, the first stent with a bioabsorbable polymer. Synergy’s drug coating and polymer are absorbed shortly after drug elution is complete at three months, leaving only the metal stent platform behind. This FDA approval is based on data from the EVOLVE II study, which showed Synergy performed as well as conventional stents at one year.

“These two new stents represent a new generation of stent technology. Both treat heart artery blockages like conventional stents, but are revolutionary in that they eliminate permanent stent components that occasionally cause long-term problems,” said SCAI Secretary Kirk Garratt, M.D., FSCAI. “These innovations highlight the interventional cardiology community’s continuous efforts to advance treatments that save lives and improve the quality of life for patients with cardiovascular disease.”

“Our goal is to ensure patients have the right treatment, at the right time,” said SCAI President James C. Blankenship, M.D., FSCAI. “Innovative technologies like bioabsorbable stents provide us with a wider array of options so we can offer patients the best possible treatment for their condition. We expect both stents will improve long-term outcomes for patients and reduce costs of treating coronary artery disease.”

For more information: www.scai.org

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init